Literature DB >> 35525889

Highly diverse phenotypes of mucopolysaccharidosis type IIIB sibling patients: effects of an additional mutation in the AUTS2 gene.

Paulina Anikiej-Wiczenbach1, Arkadiusz Mański1, Katarzyna Milska-Musa2, Monika Limanówka3, Jolanta Wierzba4, Aleksander Jamsheer5, Zuzanna Cyske6, Lidia Gaffke6, Karolina Pierzynowska6, Grzegorz Węgrzyn7.   

Abstract

Mucopolysaccharidosis type IIIB (MPS IIIB or Sanfilippo syndrome type B) is an inherited metabolic disease caused by mutations in the NAGLU gene, encoding α-N-acetylglucosaminidase. Accumulation of undegraded heparan sulfate (one of glycosaminoglycans) arises from deficiency in this enzyme and leads to severe symptoms, especially related to dysfunctions of the central nervous system. Here, we describe a case of two siblings with highly diverse phenotypes, despite carrying the same mutations (c.1189 T > G/c.1211G > A (p.Phe397Val/p.Trp404Ter)) and similar residual activities of α-N-acetylglucosaminidase; the younger patient reveals more severe phenotype; thus, these differences cannot be explained by the age and progression of the disease. Surprisingly, the whole exome sequencing analysis indicated the presence of an additional mutation in one allele of the AUTS2 gene (c.157G > A (p.Ala53Thr)) in the younger patient but not in the older one. Since mutations in this gene are usually dominant and cause delayed development and intellectual disability, it is likely that the observed differences between the MPS IIIB siblings are due to the potentially pathogenic AUTS2 variant, present in one of them. This case confirms also that simultaneous occurrence of two ultra-rare diseases in one patient is actual, despite a low probability of such a combination. Moreover, it is worth noting that apart from the genotype-phenotype correlation and the importance of the residual activity of the deficient enzyme, efficiency of glycosaminoglycan synthesis and global secondary changes in expression of hundreds of genes may considerably modulate the course and severity of MPS, especially Sanfilippo disease.
© 2022. The Author(s), under exclusive licence to Institute of Plant Genetics Polish Academy of Sciences.

Entities:  

Keywords:  Diverse phenotype; Mucopolysaccharidosis; Sanfilippo syndrome type B; Siblings

Mesh:

Substances:

Year:  2022        PMID: 35525889     DOI: 10.1007/s13353-022-00702-2

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   2.653


  16 in total

1.  Complex Changes in the Efficiency of the Expression of Many Genes in Monogenic Diseases, Mucopolysaccharidoses, May Arise from Significant Disturbances in the Levels of Factors Involved in the Gene Expression Regulation Processes.

Authors:  Zuzanna Cyske; Lidia Gaffke; Karolina Pierzynowska; Grzegorz Węgrzyn
Journal:  Genes (Basel)       Date:  2022-03-26       Impact factor: 4.141

Review 2.  Substantive validity of working memory measures in major cognitive functioning test batteries for children.

Authors:  Stacie A Leffard; Jeffrey A Miller; Joshua Bernstein; John J DeMann; Hillary A Mangis; Erika L B McCoy
Journal:  Appl Neuropsychol       Date:  2006

3.  Sanfilippo B syndrome (MPS III B): altered residual alpha-N-acetylglucosaminidase activity in an unusual sibship.

Authors:  P Di Natale; P Murino; G Pontarelli; D Salvatore; G Andria
Journal:  Clin Chim Acta       Date:  1982-07-01       Impact factor: 3.786

4.  A genetic model of substrate reduction therapy for mucopolysaccharidosis.

Authors:  William C Lamanna; Roger Lawrence; Stéphane Sarrazin; Carlos Lameda-Diaz; Philip L S M Gordts; Kelley W Moremen; Jeffrey D Esko
Journal:  J Biol Chem       Date:  2012-09-05       Impact factor: 5.157

5.  AUTS2 isoforms control neuronal differentiation.

Authors:  Galya Monderer-Rothkoff; Nitzan Tal; Marina Risman; Odem Shani; Malka Nissim-Rafinia; Laura Malki-Feldman; Vera Medvedeva; Matthias Groszer; Eran Meshorer; Sagiv Shifman
Journal:  Mol Psychiatry       Date:  2019-04-05       Impact factor: 15.992

6.  Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB.

Authors:  O L M Meijer; L Welling; M J Valstar; L H Hoefsloot; H T Brüggenwirth; A T van der Ploeg; G J G Ruijter; T Wagemans; F A Wijburg; N van Vlies
Journal:  J Inherit Metab Dis       Date:  2016-02-23       Impact factor: 4.982

Review 7.  How close are we to therapies for Sanfilippo disease?

Authors:  Lidia Gaffke; Karolina Pierzynowska; Ewa Piotrowska; Grzegorz Węgrzyn
Journal:  Metab Brain Dis       Date:  2017-09-18       Impact factor: 3.584

Review 8.  Heparan Sulfate, Mucopolysaccharidosis IIIB and Sulfur Metabolism Disorders.

Authors:  Marta Kaczor-Kamińska; Kamil Kamiński; Maria Wróbel
Journal:  Antioxidants (Basel)       Date:  2022-03-30

Review 9.  AUTS2 Syndrome: Molecular Mechanisms and Model Systems.

Authors:  Alecia Biel; Anthony S Castanza; Ryan Rutherford; Summer R Fair; Lincoln Chifamba; Jason C Wester; Mark E Hester; Robert F Hevner
Journal:  Front Mol Neurosci       Date:  2022-03-31       Impact factor: 6.261

View more
  1 in total

Review 1.  Sanfilippo Syndrome: Optimizing Care with a Multidisciplinary Approach.

Authors:  Zuzanna Cyske; Paulina Anikiej-Wiczenbach; Karolina Wisniewska; Lidia Gaffke; Karolina Pierzynowska; Arkadiusz Mański; Grzegorz Wegrzyn
Journal:  J Multidiscip Healthc       Date:  2022-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.